Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of albendazole in man.

Literature DB >> 3770064

Pharmacokinetics of albendazole in man.

S E Marriner, D L Morris, B Dickson, J A Bogan.

Abstract

The pharmacokinetics of albendazole were investigated in healthy volunteers and in patients receiving albendazole for treatment of hydatid disease. Unchanged albendazole was below detectable limits in plasma, urine, bile and cyst fluid. The major metabolite present in all fluids was the sulfoxide. Maximum concentrations of albendazole sulfoxide in plasma were very variable, probably due to variable absorption of albendazole.

Entities: Chemical Species

Mesh：

Substances：

Year: 1986 PMID： 3770064 DOI： 10.1007/bf00608219

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

14 in total

1. Metabolism of albendazole in cattle, sheep, rats and mice.

Authors: R J Gyurik; A W Chow; B Zaber; E L Brunner; J A Miller; A J Villani; L A Petka; R C Parish
Journal: Drug Metab Dispos Date: 1981 Nov-Dec Impact factor: 3.922

2. Serum and cyst concentrations of mebendazole and flubendazole in hydatid disease.

Authors: D L Morris; S E Gould
Journal: Br Med J (Clin Res Ed) Date: 1982-07-17

3. Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease.

Authors: A D Bryceson; R Woestenborghs; M Michiels; H van den Bossche
Journal: Trans R Soc Trop Med Hyg Date: 1982 Impact factor: 2.184

4. Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man.

Authors: R H Waring; S C Mitchell; R R Shah; J R Idle; R L Smith
Journal: Biochem Pharmacol Date: 1982-10-01 Impact factor: 5.858

5. The effect of dose form on the bioavailability of mebendazole in man.

Authors: M Dawson; T R Watson
Journal: Br J Clin Pharmacol Date: 1985-01 Impact factor: 4.335

6. Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man.

Authors: F Witassek; B Burkhardt; J Eckert; J Bircher
Journal: Eur J Clin Pharmacol Date: 1981 Impact factor: 2.953

7. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease.

Authors: P A Braithwaite; M S Roberts; R J Allan; T R Watson
Journal: Eur J Clin Pharmacol Date: 1982 Impact factor: 2.953

8. Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens.

Authors: P J Luder; F Witassek; K Weigand; J Eckert; J Bircher
Journal: Eur J Clin Pharmacol Date: 1985 Impact factor: 2.953

9. Efficacy of albendazole against gastrointestinal nematodes of cattle.

Authors: V J Theodorides; T Nawalinski; J Murphy; J Freeman
Journal: Am J Vet Res Date: 1976-12 Impact factor: 1.156

10. Efficacy of albendazole against Haemonchus, Nematodirus, Dictyocaulus, and Monieza of sheep.

Authors: V J Theodorides; T Nawalinski; J Chang
Journal: Am J Vet Res Date: 1976-12 Impact factor: 1.156

39 in total

1. Loss of body hair as a side effect of albendazole.

Authors: Adnan Tas; Seyfettin Köklü; Hacer Celik
Journal: Wien Klin Wochenschr Date: 2012-03 Impact factor: 1.704

2. Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft Tumors.

Authors: Gaya Hettiarachchi; Soumen K Samanta; Shane Falcinelli; Ben Zhang; Damien Moncelet; Lyle Isaacs; Volker Briken
Journal: Mol Pharm Date: 2016-01-22 Impact factor: 4.939

3. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors: Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal: Eur J Clin Pharmacol Date: 2009-06-27 Impact factor: 2.953

4. In vitro susceptibilities of the microsporidia Encephalitozoon cuniculi, Encephalitozoon hellem, and Encephalitozoon intestinalis to albendazole and its sulfoxide and sulfone metabolites.

Authors: O Ridoux; M Drancourt
Journal: Antimicrob Agents Chemother Date: 1998-12 Impact factor: 5.191

5. Ultrastructural changes in the advanced third larval stage of Gnathostoma binucleatum Almeyda-Artigas, 1991 (Nematoda: Spirurida) following albendazole and albendazole sulfoxide in vitro exposure.

Authors: Alejandro Cruz-Reyes; Bertha Gloria Ortega-Corona; Armando Zepeda-Rodríguez; Armando Pérez-Torres
Journal: Parasitol Res Date: 2011-07-09 Impact factor: 2.289

6. Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents.

Authors: Jessica D Schulz; Anna Neodo; Jean T Coulibaly; Jennifer Keiser
Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191

10. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.

Authors: Nilambra Dogra; Tapas Mukhopadhyay
Journal: J Biol Chem Date: 2012-06-28 Impact factor: 5.157